دورية أكاديمية
أعرض في EDS

Deferiprone, an iron chelator, alleviates platelet hyperactivity in patients with β-thalassaemia/HbE.

التفاصيل البيبلوغرافية
العنوان: Deferiprone, an iron chelator, alleviates platelet hyperactivity in patients with β-thalassaemia/HbE.
المؤلفون: Tran NT; Pharmacology and Toxicology Program, Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.; Pharmacy Practice Department, Faculty of Pharmacy, Haiphong University of Medicine and Pharmacy, Haiphong, Vietnam., Sutcharitchan P; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand., Janprasit J; Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand., Rojnuckarin P; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand., Morales NP; Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand., Luechapudiporn R; Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.; Center of Excellence in Natural Products for Ageing and Chronic Diseases, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
المصدر: Drugs in context [Drugs Context] 2022 Dec 12; Vol. 11. Date of Electronic Publication: 2022 Dec 12 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Bioexcel Publishing Ltd Country of Publication: England NLM ID: 101262187 Publication Model: eCollection Cited Medium: Print ISSN: 1745-1981 (Print) Linking ISSN: 17404398 NLM ISO Abbreviation: Drugs Context Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2016- : London : Bioexcel Publishing Ltd.
Original Publication: Long Hanborough, Oxon : CSF Medical Communications, c2005-
مستخلص: Background: Hyperfunctional platelets play important roles in thromboembolism in patients with β-thalassaemia/ haemoglobin E (β-thal/HbE). Our previous study revealed ex vivo inhibitory effects of deferiprone on normal platelets. Herein, we aimed to investigate the in vivo effects on platelets in patients with β-thal/HbE.
Methods: A prospective, self-controlled clinical study on 30 patients with β-thal/HbE who had received therapeutic deferiprone (20.8-94.5 mg/kg/day) was conducted. The study included a 4-week washout period followed by 4 and 12 weeks of deferiprone treatment. Platelet aggregation was performed by a turbidimetric method. Levels of deferiprone and soluble platelet (sP)-selectin in serum were measured by high-performance liquid chromatography (HPLC) and enzyme-linked immunosorbent assay (ELISA) kit, respectively.
Results: The washout period significantly enhanced platelet hyperactivity both in patients who had undergone splenectomy and in those who had not. At 2 hours following the administration of a single dose of deferiprone, platelet sensitivity to ADP and arachidonic acid was significantly reduced. The inhibitory effects of deferiprone were gradually increased over the period of 4 and 12 weeks. Deferiprone also depressed sP-selectin levels, but the effect was stable over longer follow-up periods. Correlation analysis demonstrated the relationship between serum levels of deferiprone, sP-selectin, and platelet activities induced by ADP and arachidonic acid.
Conclusion: We first demonstrated the in vivo antiplatelet effect and benefit of short-term treatment of deferiprone in patients with β-thal/HbE. The impact on thrombotic outcomes deserves further study.
Competing Interests: Disclosure and potential conflicts of interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2022/11/dic.2022-7-6-COI.pdf
(Copyright © 2022 Tran NT, Sutcharitchan P, Janprasit J, Rojnuckarin P, Morales NP, Luechapudiporn R.)
References: J Am Coll Cardiol. 2005 Apr 19;45(8):1280-6. (PMID: 15837262)
Ann Hematol. 2017 Feb;96(2):189-198. (PMID: 27900452)
Eur J Biochem. 1994 Apr 15;221(2):695-704. (PMID: 8174549)
Mediterr J Hematol Infect Dis. 2009 Dec 29;1(1):e2009029. (PMID: 21415997)
Drug Des Devel Ther. 2016 Jan 29;10:465-81. (PMID: 26893541)
Int J Mol Sci. 2021 Jun 25;22(13):. (PMID: 34202163)
Blood. 1998 Dec 1;92(11):4446-52. (PMID: 9834252)
Lancet. 2005 Oct 22-28;366(9495):1467-70. (PMID: 16243092)
Thromb Haemost. 2015 Aug 31;114(3):449-58. (PMID: 26293514)
Southeast Asian J Trop Med Public Health. 1992;23 Suppl 2:36-41. (PMID: 1298991)
Am J Hematol. 2013 Apr;88(4):251-60. (PMID: 23460233)
Southeast Asian J Trop Med Public Health. 1981 Dec;12(4):556-60. (PMID: 7344105)
Thromb Res. 2011 Sep;128(3):243-50. (PMID: 21600632)
Thromb Haemost. 2012 Dec;108(6):1109-23. (PMID: 23014768)
J Thromb Haemost. 2013 Apr 10;:. (PMID: 23574625)
Ann Hematol. 2012 Nov;91(11):1685-94. (PMID: 22847151)
Clin Appl Thromb Hemost. 2016 Sep;22(6):575-80. (PMID: 25701765)
J Med Assoc Thai. 2012 Jul;95 Suppl 7:S211-6. (PMID: 23130457)
Thromb Haemost. 2004 Nov;92(5):1052-9. (PMID: 15543333)
Biomed Pharmacother. 2022 Jan;145:112381. (PMID: 34736078)
Biomed Res Int. 2014;2014:350432. (PMID: 25121095)
Circulation. 1999 Jun 22;99(24):3118-24. (PMID: 10377074)
Thromb Res. 2007;120(6):783-9. (PMID: 17346783)
Arterioscler Thromb Vasc Biol. 2005 May;25(5):1065-70. (PMID: 15705928)
Br J Haematol. 2003 Nov;123(4):738-44. (PMID: 14616980)
Thromb Res. 2018 Sep;169:8-14. (PMID: 29990620)
Platelets. 2020 May 18;31(4):505-512. (PMID: 31366263)
Nature. 1962 Jun 9;194:927-9. (PMID: 13871375)
Clin Chem Lab Med. 2006;44(5):574-81. (PMID: 16681427)
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8070-4. (PMID: 9653141)
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):265-271. (PMID: 29222265)
Ann N Y Acad Sci. 2005;1054:317-24. (PMID: 16339680)
Southeast Asian J Trop Med Public Health. 2004 Dec;35(4):1039-44. (PMID: 15916113)
Hemoglobin. 2011;35(5-6):503-10. (PMID: 21910599)
Asian Pac J Trop Med. 2016 Nov;9(11):1035-1043. (PMID: 27890361)
Oxid Med Cell Longev. 2015;2015:537954. (PMID: 26078808)
Cold Spring Harb Perspect Med. 2012 Dec 01;2(12):a011726. (PMID: 23209183)
Clin Pharmacokinet. 2011 Jan;50(1):41-50. (PMID: 21028920)
Blood. 1991 Apr 15;77(8):1749-53. (PMID: 2015401)
Free Radic Res. 2009 May;43(5):485-91. (PMID: 19353420)
FEBS Lett. 1989 Mar 13;245(1-2):105-9. (PMID: 2494068)
Expert Rev Hematol. 2017 Jun;10(6):493-503. (PMID: 28448199)
Mediterr J Hematol Infect Dis. 2019 Jan 01;12(1):e2020011. (PMID: 31934321)
Thromb Res. 1998 Dec 15;92(6):283-6. (PMID: 9870895)
فهرسة مساهمة: Keywords: P-selectin; arachidonic acid; deferiprone; iron overload; platelet aggregation; thalassaemia
تواريخ الأحداث: Date Created: 20221222 Latest Revision: 20221223
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9753601
DOI: 10.7573/dic.2022-7-6
PMID: 36544626
قاعدة البيانات: MEDLINE
الوصف
تدمد:1745-1981
DOI:10.7573/dic.2022-7-6